Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review-Reference-Cited by-同舟云学术

Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review

Published:2021-10 Issue:4 Volume:58 Page:106410
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Zhang Huan,Liang Beibei,Wang Jin,Cai Yun^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference34 articles.

1. Epidemiology, definition and treatment of complicated urinary tract infections;Wagenlehner;Nat Rev Urol,2020

2. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline;Anger;J Urol,2019

3. Antibiotic resistance threats in the United States, 2019,2019

4. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

5. An update on the management of urinary tract infections in the era of antimicrobial resistance;Bader;Postgrad Med,2017

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and antimicrobial resistance profiles of Staphylococcus aureus isolates from burns;Molecular Biology Reports;2024-08-12

2. How to tailor recommendations on the treatment of multi-drug resistant Gram-negative infections at country level integrating antibiotic stewardship principles within the GRADE-ADOLOPMENT framework;The Lancet Infectious Diseases;2024-02

3. Assessing clinical cure of empirical piperacillin/tazobactam for ESBL urinary tract infections (ACCEPT—UTI);JAC-Antimicrobial Resistance;2023-05-03

4. Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation;Antibiotics;2023-02-09

5. Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study;Journal of Antimicrobial Chemotherapy;2023-01-24